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Objective: Nitric oxide (NO) has been shown to inhibit neointimal hyperplasia after arterial interventions in several animal
models. To date, however, NO-based therapies have not been used in the clinical arena. Our objective was to combine
nanofiber delivery vehicles with NO chemistry to create a novel, more potent NO-releasing therapy that can be used clinically.
Thus, the aim of this study was to evaluate the perivascular application of spontaneously self-assembling NO-releasing
nanofiber gels. Our hypothesis was that this application would prevent neointimal hyperplasia.
Methods: Gels consisted of a peptide amphiphile, heparin, and a diazeniumdiolate NO donor (1-[N-(3-Aminopropyl)-N-
(3-ammoniopropyl)]diazen-1-ium-1,2-diolate [DPTA/NO] or disodium 1-[(2-Carboxylato)pyrrolidin-1-yl]diazen-1-
ium-1,2-diolate [PROLI/NO]). Nitric oxide release from the gels was evaluated by the Griess reaction, and scanning
electron microscopy confirmed nanofiber formation. Vascular smooth muscle cell (VSMC) proliferation and cell death
were assessed in vitro by 3H-thymidine incorporation and Personal Cell Analysis (PCA) system (Guava Technologies,
Hayward, Calif). For the in vivo work, gels were modified by reducing the free-water content. Neointimal hyperplasia
after periadventitial gel application was evaluated using the rat carotid artery injury model at 14 days (n  6 per group).
Inflammation and proliferation were examined in vivo with immunofluorescent staining against CD45, ED1, and Ki67
at 3 days (n  2 per group), and graded by blinded observers. Endothelialization was assessed by Evans blue injection at
7 days (n  3 per group).
Results: Both DPTA/NO and PROLI/NO, combined with the peptide amphiphile and heparin, formed nanofiber gels and
released NO for 4 days. In vitro, DPTA/NO inhibited VSMC proliferation and induced cell death to a greater extent than
PROLI/NO.However, theDPTA/NOnanofiber gel only reduced neointimal hyperplasia by 45% (intima/media [I/M] area
ratio, 0.45  0.07), whereas the PROLI/NO nanofiber gel reduced neointimal hyperplasia by 77% (I/M area ratio, 0.19 
0.03, P< .05) vs control (injury alone I/M area ratio, 0.83 0.07; P< .05). Both DPTA/NO and PROLI/NO nanofiber
gels significantly inhibited proliferation in vivo (1.06 0.30 and 0.19 0.11 vs injury alone, 2.02 0.20, P< .05), yet had
minimal effect on apoptosis. Only the PROLI/NO nanofiber gel inhibited inflammation (monocytes and leukocytes). Both
NO-releasing nanofiber gels stimulated re-endothelialization.
Conclusions: Perivascular application of NO-releasing self-assembling nanofiber gels is an effective and simple therapy to
prevent neointimal hyperplasia after arterial injury. Our study demonstrates that the PROLI/NO nanofiber gel most
effectively prevented neointimal hyperplasia and resulted in less inflammation than the DPTA/NO nanofiber gel. This
therapy has great clinical potential to prevent neointimal hyperplasia after open vascular interventions in patients. ( J Vasc
Surg 2008;47:173-82.)
Clinical relevance. Atherosclerosis affects >79 million Americans, many of whom require arterial intervention; unfortu-
nately, treatment modalities often fail secondary to the development of neointimal hyperplasia, necessitating reinterven-
tion. It is well established that nitric oxide (NO) inhibits neointimal hyperplasia, but no NO-based therapies have been
clinically applied owing to various concerns. In this study, we demonstrated inhibition of neointimal hyperplasia in the
rat carotid artery balloon-injury model using the local application of a gel made fromNO and self-assembling nanofibers.
By inhibiting neointimal hyperplasia and subsequent restenosis after arterial interventions, we aim to improve long-term
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the leading cause of death and disability in the United
States. Nearly 2400 deaths per day are caused by cardiovas-
cular disease, and an estimated $432 billion was spent last
year alone in the United States on cardiovascular disease,
with a significant portion being attributed to the cost of
repeat interventions.1 Although current treatment modal-
ities improve blood flow, their long-term success is limited
because of restenosis secondary to neointimal hyperplasia.
Nitric oxide (NO) has many different vasoprotective
properties.2 These include inhibition of platelet aggrega-
tion,3 leukocyte chemotaxis,4 vascular smooth muscle cell
(VSMC) proliferation and migration,5,6 and endothelial
cell apoptosis.7 In addition, NO stimulates endothelial cell
proliferation8 and is a potent vasodilator.9 These properties
have led investigators to study the efficacy of NO-based
therapies to inhibit the development of neointimal hyper-
plasia in small- and large-animal models of arterial injury,
vein bypass grafting, and prosthetic bypass grafting.10-30
Each of these therapies has demonstrated varying degrees
of success, but none have been introduced to the clinical
arena.
Our goal is to combine nanotechnology with NO
chemistry to create a potent NO-releasing therapy that can
be used clinically to inhibit neointimal hyperplasia. The
therapy should be simple to use, safe, and free from any side
effects. Diazeniumdiolates are a class of NO donors that
release NO spontaneously when placed in an aqueous
environment.31 Each mole of these compounds releases
twomoles of NO at varying rates, depending on the specific
diazeniumdiolate.31 For our delivery vehicle, we used a
peptide amphiphile molecule that consists of a hydrophobic
fatty acid segment and a hydrophilic peptide segment con-
taining a sequence that binds to negatively charged
biopolymers, such as glycosaminoglycan heparin sulfate
(Fig 1, B).32,33 When placed in an aqueous environment,
aggregation of the hydrophobic segments induces sponta-
neous assembly of the molecules into long nanofibers. The
addition of heparin or other negatively charged molecules
promotes nanofiber growth and networking, forming a
macroscopic gel [Fig 1, C]. The nanofiber gels are biocom-
patible and serve as an elegant delivery vehicle for the
adventitial application of NO. Therefore, the aim of this
study was to examine the effect of NO-releasing nanofiber
gels on the development of neointimal hyperplasia after
arterial injury, and our hypothesis was that our NO-based
therapy would prevent neointimal hyperplasia.
METHODS
Nitric oxide-releasing nanofiber gels. The diazeni-
umdiolates evaluated in this study include disodium 1-[(2-
carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/
NO), 1-[N-(3-ammoniopropyl)-N-(n-propyl)amino]dia-
zen-1-ium-1,2-diolate (PAPA/NO), 1-[N-(3-aminopro-
pyl)-N-(3-ammoniopropyl)diazen-1-ium-1,2-diolate (DPTA/
NO), and 1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]
diazen-1-ium-1,2-diolate (DETA/NO; Fig 1, A). These
were chosen based on their NO release rates as well as theirsafety profiles.31,34 Gels were made by mixing equal vol-
umes of the following in order: peptide amphiphile (syn-
thesized as previously described32 and purified by high-
performance liquid chromatography) solution in ultrapure
water (3-wt %), 1-mol/L diazeniumdiolate (prepared as
previously described35,36) in phosphate-buffered saline
(PBS), and heparin in PBS (2 wt %, heparin sodium salt,
Sigma, St Louis, Mo).
To determine NO production from each of the gels,
100 L of gel was submerged in 500 L of fresh PBS and
maintained at 37°C. Every 24 hours, the supernatant was
removed to measure nitrite release (an indirect determinant
of NO production) by the Griess reaction.37 Another 500
L of fresh PBS was then added each day, and the cycle was
repeated until the gels no longer released NO.
For in vivo experiments, the gel recipe was modified to
reduce free-water content. PROLI/NO or DPTA/NO
(10 mg) was dissolved directly in 100 L of 3-wt % heparin
(in PBS, pH 12.1 and 10.4, respectively, room tempera-
Fig 1. Our approach to inhibiting neointimal hyperplasia uses
two components: (A) diazeniumdiolate nitric oxide donors,
PROLI/NO, PAPA/NO, DPTA/NO, and DETA/NO (half-
lives listed are for physiologic conditions, 37°C and pH 7.4) and
(B) heparin-binding peptide amphiphile. C, The peptide amphi-
philes spontaneously form nanofibers in aqueous solutions when
exposed to heparin, as depicted in this drawing. PROLI/NO,
Disodium 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-
diolate;PAPA/NO, 1-[N-(3-ammoniopropyl)-N-(n-propyl)amino]
diazen-1-ium-1,2-diolate; DPTA/NO, 1-[N-(3-aminopropyl)-N-
(3-ammoniopropyl)]diazen-1-ium-1,2-diolate; DETA/NO, 1-[N-
(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-
diolate.ture). This solution was added to 100 L of 4.5-wt %
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ized water. The final solution was placed on a glass slide to
gel ex vivo for 10 minutes before application. The final pH
for the PROLI/NO and DPTA/NO nanofiber gels was
10.87 and 10.27, respectively. The control gel wasmade up
of 100L of 3-wt% heparin and 100L of 4.5-wt% peptide
amphiphile; it did not contain PROLI/NOorDPTA/NO.
Scanning electron microscopy. Gels were dehy-
drated in a graded ethanol series and dried by the critical
point method in a Samdri 790A critical point drying appa-
ratus (Tousimis Research Corporation, Rockville, Md).
The dried samples were sputter-coated with gold/palla-
dium (3nM) using a Cressington Sputter Coater (Cressing-
ton Scientific Instruments, Watford, UK) before imaging
with a Hitachi S-4800 scanning electron microscope (Hi-
tachi Kokusai Electric America, Woodbury, NY).
Cell culture. Vascular smooth muscle cells were iso-
lated and cultured from the abdominal aorta of Sprague-
Dawley rats (Harlan, Indianapolis, Ind) using the explant
method38 and maintained as previously described.37
Proliferation assay. Vascular smooth muscle cells
plated in 12-well plates (4  104 cells/well) were growth-
arrested for 24 hours with starvation media that contained
no fetal bovine serum. Cells were then exposed to media
containing one of the two NO donors (PROLI/NO or
DPTA/NO powder) in the presence of tritiated 3H-thymi-
dine (5 Ci/mL, PerkinElmer, Wellesley, Mass) for an
additional 24 hours. The incorporation of 3H-thymidine
into trichloroacetic acid–precipitated DNA was quantified
by scintillation counting.
Cell death assay. Vascular smooth muscle cells plated
in 6-well plates (1  105 cells/well) were growth-arrested
for 24 hours with starvation media, after which they were
exposed to media with one of the two NO donors
(PROLI/NO or DPTA/NO powder) for 24 hours. Cells
were trypsinized, collected, pelleted, and resuspended in
PBS (250 L). This suspension (40 L) was added to 160
L of Guava ViaCount Reagent, and cell death was assessed
using the Personal Cell Analysis (PCA) system (Guava
Technologies, Hayward, Calif).
Animal surgery. All animal procedures were per-
formed in accordance with the Guide for the Care and Use
of Laboratory Animals (National Institutes of Health Pub-
lication 85-23, 1996) and approved by the Northwestern
University Animal Care and Use Committee. Adult male
Sprague-Dawley rats weighing 350 to 400 g underwent
carotid artery balloon injury as previously described.20,37
After injury and restoration of flow, one of the NO-eluting
nanofiber gels or control therapies (200 L) was applied to
the external surface of the injured common carotid artery
and the neck incision was closed. Rats were euthanized at 3
days (n  2 per group), 7 days (n  3 per group), and 14
days (n  6 per group).
Tissue processing. Carotid arteries were harvested af-
ter in-situ perfusion-fixation with PBS (250 mL) and 2%
paraformaldehyde (500 mL). Tissue was processed as pre-
viously described.20Morphometric analysis. Carotid arteries harvested at
14 days were examined histologically for evidence of neo-
intimal hyperplasia using routine hematoxylin and eosin
staining. A modified Verhoeff von Gieson stain was used to
evaluate elastin and collagen. Digital images were collected
with light microscopy using an Olympus BHT microscope
(Melville, NY) with 4, 10, and 40 objectives. Six
evenly spaced sections through each injured carotid artery
were morphometrically analyzed. Lumen area, intimal area
(I), medial area (M), and external elastic lamina circumfer-
ence were measured (arbitrary units) using ImageJ software
(National Institutes of Health, Bethesda, Md).
Immunohistochemistry. Carotid arteries harvested
at 3 days were examined for evidence of inflammation and
proliferation using immunofluorescent staining. Sections
fixed with 2% paraformaldehyde or acetone were perme-
abilized with Triton-X100 in PBS. Sections were then
blocked with goat serum (Sigma, St Louis, Mo) in 0.5%
bovine serum albumin (Vector, Burlingame, Calif). Pri-
mary antibody in bovine serum albumin was applied for 1
hour: anti-ED1 (macrophage, 1:500; Serotec, Raleigh,
NC), anti-CD45 (lymphocyte, 1:500; BD Pharmingen,
San Diego, Calif) or anti-Ki67 (1:100; BD Biosciences, San
Jose, Calif). Secondary antibody in bovine serum albumin
was applied for 1 hour (goat antimouse Alexa Fluor 555,
1:3000; Invitrogen, Carlsbad, Calif). Coverslips were af-
fixed with gelvatol.
From each animal, six sections from the area of injury
were stained. Eight independent blinded observers qualita-
tively graded the inflammation and proliferation in each
treatment group on a scale of 0 to 3. Digital images were
acquired using a Zeiss LSM-510 microscope (Hallberg-
moos, Germany) at 40.
Apoptosis was evaluated in carotid arteries harvested at
3 and 14 days by terminal deoxynucleotidyl transferase-
mediated deoxy uridine triphosphate biotin nick-end label-
ing (TUNEL) using a commercial system according to the
manufacturer’s instructions (DeadEnd Colorimetric
TUNEL system; Promega, Madison, Wis).
Endothelialization. Rat carotid arteries were har-
vested at 7 days. Thirty minutes before euthanasia, rats
received an intravenous injection of Evans blue dye (0.5mL
of 0.5%, Sigma). Carotid arteries were procured after in-situ
perfusion with 500 mL of PBS and photographed. Blue
staining indicated area of increased endothelial permeabil-
ity. Images were qualitatively analyzed by two independent
observers.
Statistical analysis. Results are expressed as mean 
standard error of the mean. Differences between multiple
groups were analyzed using one-way analysis of variance
with the Student-Newman-Keuls post hoc test for all pair-
wise comparisons using SigmaStat software (SPSS, Chi-
cago, Ill). Statistical significance was assumed when P 
.05.
RESULTS
Nitric oxide release from nanofiber gels. Initially,
the diazeniumdiolate nanofiber gels tested included
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When combined with peptide amphiphile and heparin,
DETA/NO and PAPA/NO did not form a consistent gel;
instead, most of the product remained liquid. We therefore
used only the PROLI/NO and DPTA/NO nanofiber gels.
To determine the amount and duration of NO release
from the gels (100 L), Griess reactions were conducted.
Nitrite release was observed for 4 days from both the
PROLI/NO and DPTA/NO nanofiber gels, with most of
the nitrite release occurring in the first 2 days (Fig 2, A).
The PROLI/NO nanofiber gel appeared to have steady
nitrite release for the initial 2 days, whereas the DPTA/NO
nanofiber gel had similar release on day 1 compared with
the PROLI/NO nanofiber gel, but on day 2, the nitrite
release doubled. Both PROLI/NO and DPTA/NO nano-
fiber gels had a significant decline in NO release on day 3
and 4, and by day 5, there was no difference compared with
control gels. Scanning electron microscopy of the nanofi-
ber, PROLI/NO nanofiber, and DPTA/NO nanofiber
gels revealed distinct nanofiber formation (Figs 2, B-D).
PROLI/NO and DPTA/NO inhibit vascular
smooth muscle cell proliferation in vitro. In an effort to
characterize the effects of PROLI/NO and DPTA/NO on
proliferation of VSMC, an in vitro 3H-thymidine prolifer-
ation assay was conducted (Fig 3, A and B). The highest
concentration of PROLI/NO (1000M) inhibited VSMC
proliferation by 32% (P .05). Although there was a trend
Fig 2. A, Nitrite release from nanofiber, PROLI/NO nanofiber,
and DPTA/NO nanofiber gels in vitro, determined using the
Griess reaction (n 2 per group). Data are representative of three
separate experiments. Scanning electron microscopy images
(4000 original magnification) of the (B) nanofiber gel, (C)
PROLI/NO nanofiber gel, and (D) DPTA/NO nanofiber gel.
NO, Nitric oxide. See Fig 1 for the expansion of the abbreviations
PROLI/NO and DPTA/NO.toward less proliferation with lower concentrations ofPROLI/NO (125 to 500M), there was no statistically
significant effect vs control. In contrast, the longer-acting
NO donor, DPTA/NO, induced a concentration-depen-
dent inhibition of VSMC proliferation (125 to 1000M; P
 .05). Furthermore, the antiproliferative effect of
DPTA/NO was more potent than PROLI/NO:
DPTA/NO inhibited VSMC proliferation by 51% to 78%
(P  .05).
PROLI/NO and DPTA/NO induce minimal vas-
cular smooth muscle cell death in vitro. To determine if
PROLI/NO andDPTA/NO induce VSMCdeath in vitro,
the Guava PCA system was implemented (Fig 3, C and D).
Although not statistically significant, there was a trend
towards increased cell death with increasing concentrations
of PROLI/NO (125 to 1000M). At lower concentra-
tions, DPTA/NO (125 to 500M) did not induce statis-
tically significant VSMC death. However, at the highest
concentration evaluated, DPTA/NO (1000M) induced
21.4%  0.9% cell death in VSMCs (P  .05).
Nitric oxide-releasing nanofibers inhibit neointi-
mal hyperplasia in the rat carotid artery injury model.
Because of the multiple-day NO-release and the ability of
PROLI/NO and DPTA/NO to form gels with peptide
amphiphile and heparin, we examined the in vivo effect of
gel application on neointimal hyperplasia after rat carotid
artery balloon injury (Fig 4). The gel was applied to the
adventitial surface of the carotid artery only. Balloon injury
produced reproducible neointimal hyperplasia at 14 days
(Table; Fig 4, A). With the application of the nanofiber
control gel, there was no statistically significant difference
vs injury alone for either the intimal area (3.20  0.34 vs
3.63  0.35, respectively) or the I/M area ratio (0.69 
0.07 vs 0.83 0.07, respectively). However, with applica-
tion of PROLI/NO and DPTA/NO nanofiber gels, neo-
intimal hyperplasia was significantly inhibited. The
PROLI/NO nanofiber gel showed an 80% reduction of
intimal area (0.71  0.14 vs injury alone, P  .05) and a
77% reduction of I/M area ratio (0.19  0.03 vs injury
alone, P  .05). Although not as impressive, the
DPTA/NO nanofiber gel demonstrated modest inhibition
of neointimal hyperplasia: 40% reduction of intimal area
(2.19  0.34 vs injury alone, P  .05) and 45% reduction
of I/M area ratio (0.45  0.07 vs injury alone, P  .05).
There was a statistically significant difference in inhibition
of neointimal hyperplasia between PROLI/NO and
DPTA/NO nanofiber gels (P  .05). No statistically sig-
nificant difference was found between the medial areas for
injury alone, nanofiber control gel, and DPTA/NO nano-
fiber gel groups; however, the PROLI/NO nanofiber gel
treatment resulted in a 15% medial area reduction vs injury
alone (P  .05). There was no difference in the circumfer-
ence of the external elastic lamina between the groups. It
therefore appears that our NO-nanofiber gels had very little
effect on adaptive vascular remodeling but had a large effect
on inhibiting the development of neointimal hyperplasia.
Nitric oxide-releasing nanofiber gels inhibit inflam-
mation and proliferation in vivo. To characterize the
effect of the PROLI/NO and DPTA/NO nanofiber gels
d DP
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immunohistochemical staining for markers of inflamma-
tion and proliferation at 3 days (Fig 5). Similar numbers of
monocytes (anti-ED1) were seen in the injury alone, nano-
fiber, and DPTA/NO groups. In the PROLI/NO group,
however, there was a reduction in the observed mononu-
clear infiltrate vs injury alone. When the CD45-positive
leukocytes were examined, the injury alone and
DPTA/NO groups appeared to have similar leukocyte
infiltration; however, nanofiber and PROLI/NOnanofiber
groups had fewer leukocytes compared with injury alone.
To summarize, the DPTA/NO nanofiber gel appeared to
have no effect on inflammation compared with injury
alone, whereas the PROLI/NO nanofiber gel appeared to
inhibit inflammation after arterial injury.
Next we determined the effect of the nanofiber gels on
cellular proliferation (anti-Ki67) in vivo. Injury alone ex-
hibited the most proliferation, and similar levels were ob-
served with the nanofiber gel; most of the proliferating cells
appeared to be in the adventitia. Both PROLI/NO and
DPTA/NO nanofiber gels demonstrated an inhibition of
cellular proliferation in vivo, and the effect appeared to be
greatest on the adventitial cells; however, the PROLI/NO
nanofiber gel seemed to inhibit proliferation dramatically,
whereas the DPTA/NO nanofiber gel inhibited prolifera-
tion modestly. This pattern mirrored the effect on neointi-
Fig 3. A, B,Effect of PROLI/NO andDPTA/NOon v
in vitro. Proliferation and cell death were quantified usi
(PCA) system (Hayward, Calif), respectively, (n 3 per
Fig 1 for expansion of the abbreviations PROLI/NO anmal hyperplasia.Nitric oxide-releasing nanofiber gels induce little
apoptosis in vivo. We sought to determine whether the
NO-releasing nanofiber gels limited neointimal hyperplasia by
inducing apoptosis in vivo. Sections stained using TUNEL
did not reveal any distinct patterns and showed little apoptosis
among the different treatment groups (data not shown).
These data are fairly consistent with the in vitro data.
Nitric oxide-releasing nanofiber gels stimulate re-
establishment of the endothelial barrier after arterial
injury. To determine the effect of the NO-releasing nano-
fiber gels on the endothelium after balloon injury, animals
were injected with Evans blue dye premortem; arterial
segments with increased endothelial permeability stained
blue (Fig 6). By qualitative analysis, untreated carotid ar-
teries and arteries treated with nanofiber gel exhibited the
greatest amount of blue staining. Arteries treated with
PROLI/NO nanofiber gel demonstrated a very small
amount of blue staining, and those treated with
DPTA/NO nanofiber gel had little to no staining, suggest-
ing little endothelial permeability by 7 days. These data
suggest that both NO-releasing nanofiber gels stimulate
the re-establishment of an intact endothelial layer.
DISCUSSION
Neointimal hyperplasia develops after arterial injury and
endothelial denudation through a series of events that in-
ar smoothmuscle cell proliferation and (C, D) cell death
itiated thymidine and the Guava Personal Cell Analysis
). Data are representative of 3 separate experiments. See
TA/NO.ascul
ng tr
groupcludes platelet adherence and aggregation, leukocyte chemo-
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tion.39-42 This cascade often results in luminal narrowing and
restenosis. We examined the effects of two NO-releasing
nanofiber gels on neointimal hyperplasia in an attempt to
develop a simple-to-use, potent, NO-based clinical therapy.
An unexpected result from this research is that in vitro,
PROLI/NO had little effect, whereas DPTA/NO demon-
strated inhibition of VSMC proliferation and induction of
cell death. The NO-eluting nanofiber gels created using
these two diazeniumdiolates exhibited prolonged nitrite
Fig 4. Rat carotid artery sections from uninjured, in
DPTA/NO nanofiber gel animals euthanized at 14 days
magnification) from each group using routine staining w
(VvG). B, Graphic representation of intima/media (I/M
Morphometric analysis conducted on 6 sections per rat. U
PROLI/NO nanofiber gel; DNG, DPTA/NO nanofibe
of the abbreviations PROLI/NO and DPTA/NO.
Table. Morphometric analysis of carotid arteries 14 days af
Treatment group* Circumference Lumen area I
Injury alone 1.64  0.03 8.53  0.77 3.
Nanofiber gel 1.64  0.02 12.00  0.31† 3.
PROLI/NO
nanofiber gel
1.68  0.02 15.57  0.43† 0.
DPTA/NO
nanofiber gel
1.68  0.03 12.75  0.66† 2.
I, Intimal;M,Medial; PROLI/NO, disodium 1-[(2-carboxylato)pyrrolidin-
niopropyl)]diazen-1-ium-1,2-diolate
*All groups had 6 rats, 6 sections per rat. Data are presented as mean  SE
†P  .05 vs injury alone.
‡P  .05 vs DPTA/NO nanofiber gel.release (a decomposition product of NO) during a 4-dayperiod, indicating either (1) an increased half-life for the
NO donor in the nanofiber gel environment by shielding it
from hydrogen ions or (2) prolonged retention of NO itself
within the gel. NO retention within the hydrophobic cores
of the nanofiber would be expected given the low dipole
moment of NO. Furthermore, Moller et al43 demonstrated
NO partitioning to the hydrophobic phase of biologic
membranes. Although the exact disposition of NO and its
diazeniumdiolate precursor in the nanofiber gels will re-
quire further study, an enhanced therapeutic effect of NO
alone, nanofiber gel, PROLI/NO nanofiber gel, and
6 per group). A, Representative sections (100 original
ematoxylin and eosin (H&E) and Verhoff-van Gieson
ea ratio presented with the standard error of the mean.
are arbitrary. IA, Injury alone,NG, nanofiber gel, PNG,
NO, Nitric oxide. See Fig 1 for the complete expansion
alloon injury
al area Medial area I/M area ratio I/(IM)
0.35 4.37  0.17 0.83  0.07 0.42  0.02
0.34 4.56  0.16 0.69  0.07 0.38  0.02
0.14†‡ 3.70  0.17†‡ 0.19  0.03†‡ 0.14  0.02†
0.34† 4.59  0.17 0.45  0.07† 0.26  0.03†
iazen-1-ium-1,2-diolate;DPTA/NO, 1-[N-(3-aminopropyl)-N-(3-ammo-jury
(n
ith h
) ar
nits
r gel.ter b
ntim
63 
20 
71 
19 
1-yl]d
.in this novel delivery vehicle is evident.
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inhibition of neointimal hyperplasia using NO-based ap-
proaches in animal models.10-30 These approaches include
inhalational NO therapy,10 L-arginine supplementa-
tion,11-13 systemic administration of NO donors,14 nitric
oxide synthase gene therapy,15-21 and local delivery of
intraluminal and perivascular NO donors.22-27,30 How-
ever, none of these therapies have been implemented clin-
ically because of various concerns, including lack of signif-
icant and durable effect, systemic side effects, safety
concerns, and complicated delivery schemes.
Our novel therapy uses periadventitial delivery. Be-
cause NO is freely diffusible, it penetrates all layers of the
vascular wall. Thus, adventitial delivery effectively reduces
neointimal hyperplasia by inhibiting both adventitial fibro-
blasts and medial VSMCs. Another advantage of localized
therapy is that the NO delivery is concentrated at the site of
injury. This avoids systemic side effects, such as hypoten-
Fig 5. Immunofluorescence staining for markers of infla
original magnification) from uninjured, injury alone, n
nanofiber gel treatment groups (n 2 per group, 3 sectio
lamina is green. Graphic representation of scoring by 8 b
(C) leukocytes (anti-CD45), and (D) proliferation (an
animal. U, Uninjured; IA, injury alone; NG, nanofiber
DNG, DPTA/NO nanofiber gel. See Fig 1 for the 
DPTA/NO.sion, coagulopathy, and headaches.Kown et al30 demonstrated that L-arginine polymer-
treated vein grafts exhibited 43% less neointimal hyperpla-
sia in a rabbit vein bypass model.30 Kaul et al26 applied a
biodegradable polymer (polylactic-polyglycolic acid) con-
taining spermine/NO (2.5% w/w) to the periadventitial
surface of balloon-injured rat ileofemoral arteries, which
resulted in a 69% reduction in intimal area. Chaux et al24
used the same biodegradable polymer with spermine/NO
in a rabbit jugular vein grafting model. At 28 days there was
a 41% reduction in intimal area vs control.24
Two studies from Dr West’s group utilized polyethyl-
ene glycol (PEG)-based hydrogels covalentlymodifiedwith
S-nitrosocysteine groups.44,45 After rat carotid artery bal-
loon injury, the hydrogels were applied to the periadventi-
tial arterial surface. Photopolymerization of the hydrogels
was conducted with an ultraviolet light, andNO release was
observed for approximately 24 hours. A 75% inhibition of
neointimal hyperplasia was seen in arteries harvested at 14
tion and proliferation.A,Representative sections (400
ber gel, PROLI/NO nanofiber gel, and DPTA/NO
r animal). Positive staining is indicated by red and elastic
d observers (scale, 0-3) for (B) monocytes (anti-ED1),
7). Each data point represents scoring for a particular
O, nitric oxide; PNG, PROLI/NO nanofiber gel; and
lete expansion of the abbreviations PROLI/NO andmma
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compdays. These studies thus demonstrate, similar to our study,
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neointimal hyperplasia.
Our NO-eluting nanofiber therapy has several addi-
tional attractive features. The first is the use of customizable
nanostructures formed from peptide amphiphiles as a de-
livery vehicle. These molecules spontaneously assemble
into nanofiber gels under physiologic conditions, and sim-
ilar nanofibers support growth and differentiation of vari-
ous cell types in vitro.46,47 The spontaneous formation is
important because it requires no additional activators, such
as ultraviolet light. Thus, our approach is simple to use.
Peptide amphiphile nanofibers have also been used as
bioactive coatings for tissue engineering implants,48 and
preliminary testing in murine models has revealed no large-
scale immune response to the nanofibers.49 Rajangam et
al32 recently reported a peptide amphiphile molecule that
was designed to bind heparin. Heparin-binding nanofiber
gels were shown in vitro and in vivo to bind and control the
bioavailability of various growth factors (vascular endothe-
lial growth factor and fibroblast growth factor-2),32 pre-
senting another potential therapeutic axis for inhibiting
neointimal hyperplasia. In vivo testing of this molecule in
other animal models is underway, and thus far has revealed
no significant biocompatibility issues (unpublished data).
The other component of our approach uses diazenium-
diolates. Diazeniumdiolates are advantageous because of
their predictable, spontaneous NO release in an aqueous
environment, and they can be tailored to a wide range of
NO release rates.31 Thus, our unique approach to marry
these two entities—peptide amphiphiles and the diazeni-
umdiolates—has several beneficial therapeutic qualities.
Another important physical characteristic of our therapy is
that the peptide amphiphile and heparin solutions are stable
when refrigerated. When combined with the NO-heparin
solution, the self-assembling nature of the peptide amphi-
phile system allows the nanofibers to form a gel nearly
instantly and thus requires very little preparation time.
Fig 6. Re-endothelialization of injured rat carotid arteries.
Groups include injury alone and injury with nanofiber,
PROLI/NO nanofiber, or DPTA/NO nanofiber gels (n  3 per
group). Arteries were procured at 7 days postinjury. Arterial areas
lacking endothelium stain blue (arrow). See Fig 1 for the complete
expansion of the abbreviations PROLI/NO and DPTA/NO.Finally, when the therapy is applied to the injured area, thegel adheres, ensuring that the treatment reaches the tar-
geted location as accurately as possible.
An interesting finding is the opposing results from the
in vitro and in vivo studies. DPTA/NO more effectively
inhibited VSMC proliferation and induced VSMC cell
death in vitro, yet the PROLI/NO nanofiber gel more
successfully inhibited neointimal hyperplasia in vivo. This
may be occurring for several reasons. The PROLI/NO
powder has a very short half-life; therefore, its effect in vitro
may not be sustained enough to exert an effect. When
administered as part of a gel, the PROLI/NOnanofiber gel
was shown to release NO for 4 days, and this prolonged
NO release may partially increase the effect seen. The
PROLI/NO nanofiber gel also inhibited inflammation, as
evidenced by less monocyte and leukocyte infiltration,
whereas the DPTA/NO nanofiber gel did not. Inhibition
of leukocyte infiltration would impact the arterial injury
cascade by limiting growth factor and cytokine secretion
and subsequent VSMC proliferation and migration. Thus,
these properties of the PROLI/NO nanofiber gel may
contribute to its heightened efficacy.
Another fascinating aspect of this research is the effec-
tiveness of the NO donors with use of the nanofiber deliv-
ery vehicle. Prior work in our laboratory examined the
effect of 20 mg of PROLI/NO powder applied to the
adventitial surface of the rat carotid artery after balloon
injury and demonstrated 86% inhibition of neointimal hy-
perplasia at 14 days, as measured by the I/M area ratio
(unpublished data). In this study, half as much
PROLI/NO (10 mg) resulted in a similar degree of inhi-
bition (77%), and this may be because the gel application is
more controlled and allows for more even distribution of
the drug on the entire external surface of the artery. In
addition, the peptide amphiphile is known to specifically
bind heparin, an inherent property that may increase the
local heparin concentration at the site of injury and poten-
tiate the antiproliferative actions of NO. There is prece-
dence for combining diazeniumdiolate NO donors with
heparin: Saavedra et al50 synthesized a heparin-methoxym-
ethyl-PIPERAZI/NO conjugate, which released NO on
hydrolysis and inhibited adenosine 5=-diphosphate-in-
duced platelet aggregation but also retained significant
heparin-like anticoagulant properties in vitro. The two
complementary antithrombotic mechanisms are likely oc-
curring with application of our treatment gels as well.
Regardless, we found that use of this nanofiber gel delivery
vehicle provided advantages over the PROLI/NO powder
alone and will enable transition of this therapy to the
clinical arena.
Although our NO-releasing nanofiber gel is an exciting
therapeutic candidate, one potential limiting factor is the
potentiated antithrombotic actions of heparin and NO.
Because both of these products inhibit platelet adherence
and aggregation, their combination may lead to increased
bleeding if proper hemostasis is not achieved. In five ani-
mals treated with the DPTA/NO nanofiber gel and three
animals treated with PROLI/NO nanofiber gel, a superfi-
cial hematoma was observed at euthanasia (14 days) vs
JOURNAL OF VASCULAR SURGERY
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heparin could be substituted with another sulfated glycos-
aminoglycan without antithrombin-binding properties that
would also induce gel formation. One such potential sub-
stitute is heparan sulfate; however, it is much more costly
than heparin.
Another limitation is that this study only compares the
outcome of one delivery vehicle, namely the self-assembled
nanofiber gel. A future study could analyze the efficacy of
this gel delivery vehicle against other gel delivery vehicles
using the same NO donor. This form of analysis would
provide data with respect to the gel delivery vehicle alone.
Finally, we do not know if any of the hydrolyzed
breakdown products or if the peptide amphiphile or by-
products have effects on the vasculature or, specifically,
neointimal hyperplasia. Some of these molecular byprod-
ucts include the amino acids alanine, glycine, lysine,
leucine, and arginine; salts from sodium hydroxide, hydro-
chloric acid, and possibly trifluoroacetic acid also may be
present. The nanofiber gel alone serves as a control, and no
statistically significant reduction in neointimal hyperplasia
was observed with its application, suggesting that the pep-
tide amphiphile products do not affect results. This, how-
ever, is something that may need to be examined more
specifically in the future.
CONCLUSION
By combining NO and nanotechnology, we created a
novel approach that successfully inhibited neointimal hy-
perplasia in the rat carotid artery injury model. Although
both NO-eluting nanofiber gels inhibited neointimal hy-
perplasia, the PROLI/NO nanofiber gel was clearly more
effective. Before this therapy can be used in the clinical
arena, it must be evaluated in a large-animal model, and
long-term studies will need to be conducted for toxicity as
well as efficacy. Overall, this therapy has promising clinical
potential as a novel NO-based therapy for open vascular
and cardiovascular surgical procedures for the prevention of
restenosis and the associated patient morbidity.
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